Introduction
The treatment of tricuspid regurgitation includes medical therapy, treatment of the underlying cause, catheter-based procedures, and surgery. The choice of treatment depends on why the tricuspid valve is leaking, how much blood is flowing backward, whether symptoms are present, and whether the right side of the heart has begun to enlarge or weaken. In general, treatment aims to reduce the volume load on the right ventricle, correct contributors such as pulmonary hypertension or atrial fibrillation, and restore more effective one-way valve function.
Tricuspid regurgitation occurs when the tricuspid valve does not close properly during systole, allowing blood to move backward from the right ventricle into the right atrium. Over time, this backward flow raises venous pressure, contributes to fluid retention, and can stretch the right-sided chambers. Treatment strategies are therefore directed not only at relieving congestion and symptoms, but also at interrupting the structural and hemodynamic changes that allow the regurgitation to worsen.
Understanding the Treatment Goals
The main goals of treatment are to reduce symptoms, slow or prevent progression, and limit complications caused by chronic right-sided volume overload. When regurgitation is severe enough to raise right atrial and systemic venous pressures, patients may develop swelling, liver congestion, abdominal fluid accumulation, and reduced exercise tolerance. Therapies that reduce venous congestion or improve valve competence can lower these pressures and improve circulation.
Another goal is to address the mechanism behind the valve leak. Tricuspid regurgitation is often functional rather than purely structural. In functional disease, the valve leaflets may be anatomically intact, but the right ventricle or right atrium enlarges, the annulus stretches, or the papillary muscle geometry changes, preventing complete closure. Treatment is therefore aimed at the disease process that distorts the valve apparatus. If the trigger is pulmonary hypertension, atrial fibrillation, left-sided heart disease, or cardiomyopathy, managing those conditions can reduce the force or geometry changes that worsen regurgitation.
In advanced disease, the goal shifts toward preserving right ventricular function and preventing irreversible remodeling. Once chronic volume overload causes marked right ventricular dilation and dysfunction, valve correction becomes more difficult and outcomes worsen. This is one reason treatment decisions are often made before severe chamber damage develops.
Common Medical Treatments
Medical treatment does not directly repair the valve, but it can reduce the physiological consequences of regurgitation and sometimes lessen its severity when the cause is functional. The most common medications are diuretics. Diuretics increase sodium and water excretion by the kidneys, lowering intravascular volume and reducing venous congestion. By decreasing preload and systemic fluid accumulation, they relieve edema, ascites, and hepatic congestion. They do not close the valve, but they reduce the pressure burden created by backward flow.
When tricuspid regurgitation is associated with heart failure, guideline-directed therapy for the underlying cardiac disorder is used. In left-sided heart failure, therapies such as beta blockers, ACE inhibitors, angiotensin receptor blockers, ARNI therapy, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors improve ventricular performance and reduce filling pressures. Lower left-sided pressures can reduce pulmonary venous and pulmonary arterial pressure, which in turn reduces strain on the right ventricle. This can indirectly improve functional tricuspid regurgitation by limiting dilation of the right-sided chambers.
If pulmonary hypertension is driving the regurgitation, treatment is directed at the cause of the elevated pulmonary pressure. Lowering resistance in the pulmonary circulation reduces right ventricular afterload, which can limit right ventricular dilation and help the tricuspid valve leaflets meet more effectively during systole. In select patients with pulmonary arterial hypertension, targeted vasodilator therapies are used to alter pulmonary vascular tone and remodeling, although these are chosen according to the specific type of pulmonary hypertension.
Rate or rhythm control for atrial fibrillation is another common medical approach. Chronic atrial fibrillation can enlarge the right atrium and stretch the tricuspid annulus, producing atrial functional tricuspid regurgitation even without major right ventricular disease. Restoring sinus rhythm or controlling a rapid ventricular response can reduce atrial pressure and limit annular dilation. Anticoagulation may also be used when atrial fibrillation is present, not to treat the regurgitation itself, but to reduce thromboembolic risk associated with the arrhythmia.
In infective endocarditis involving the tricuspid valve, antimicrobial therapy is central. Antibiotics treat the bacterial infection that damages valve tissue and prevents proper leaflet coaptation. In these cases, the biological target is the infectious process rather than hemodynamic overload. Medical therapy alone may be sufficient in some infections, but structural destruction may require procedural intervention.
Procedures or Interventions
Procedural treatment is considered when regurgitation is severe, symptomatic, progressive, or associated with structural valve damage. Surgery remains the classic definitive treatment. Surgical repair is generally preferred when feasible because it preserves the native valve apparatus and avoids some of the long-term problems associated with valve replacement. Repair commonly includes annuloplasty, in which a ring or band is placed around the tricuspid annulus to reduce its diameter. This directly counteracts annular dilation, which is a major mechanism of functional regurgitation. By bringing the valve leaflets closer together, annuloplasty improves leaflet coaptation and reduces backward flow.
When repair is not possible, valve replacement may be performed. Replacement removes the diseased valve and inserts a mechanical or bioprosthetic valve to re-establish one-way flow. This changes the structure of the valve apparatus more radically than repair. It is typically reserved for cases in which leaflet destruction, marked tethering, or prior failed repair makes durable correction unlikely. Replacement eliminates regurgitation through the native valve but introduces issues related to prosthetic durability, thrombosis risk, and the need for anticoagulation in many mechanical valves.
Procedural intervention is also used for endocarditis when infection causes persistent valve destruction, large vegetations, embolic risk, or uncontrolled infection. Surgery can remove infected tissue, restore valve competence, and reduce the ongoing inflammatory burden. In these situations, the rationale is both mechanical and microbiological: the infected and damaged tissue is no longer capable of maintaining effective valve function.
Transcatheter therapies are increasingly used in selected patients who are poor surgical candidates. Transcatheter edge-to-edge repair places a device that approximates the tricuspid leaflets, creating a more effective seal during systole. This reduces the regurgitant orifice without open-heart surgery. Other catheter-based systems may reduce annular size or replace the valve through venous access. These approaches are designed to alter the valve geometry and restore coaptation while avoiding the physiologic stress of open surgery, which is particularly relevant in older patients or those with multiple comorbidities.
In some patients, intervention is timed before right ventricular failure becomes advanced. This is because once the ventricle is markedly dilated and contractile function is poor, correcting the valve may no longer fully reverse the downstream hemodynamic consequences. The procedure is therefore not only about reducing leakage, but also about preserving the ability of the right ventricle to pump effectively against the pulmonary circulation.
Supportive or Long-Term Management Approaches
Long-term management focuses on monitoring the progression of valve dysfunction and the response of the right heart. Periodic echocardiography is central because it shows the degree of regurgitation, annular size, right atrial and right ventricular dimensions, and right ventricular function. These measurements reflect the physiological impact of the leak and help determine whether the condition remains compensated or is causing progressive remodeling.
Ongoing management of volume status is often necessary in chronic disease. By preventing sustained venous congestion, diuretic therapy helps limit peripheral edema and abdominal fluid accumulation. This does not change the valvular anatomy, but it reduces the consequences of elevated right-sided pressures and can improve organ perfusion. In patients with hepatic congestion, chronic venous unloading may reduce further liver injury caused by elevated hepatic venous pressure.
Supportive management also includes treatment of associated disorders that maintain the regurgitant state. Control of blood pressure, management of sleep apnea, treatment of left-sided valvular disease, and reduction of pulmonary pressures all influence the load on the right ventricle and annulus. These measures are not direct valve therapies, but they alter the forces that drive valve incompetence.
In chronic disease, follow-up is important because tricuspid regurgitation can progress silently. Symptoms may appear late, after significant remodeling has already occurred. Repeated assessment allows clinicians to identify increasing chamber enlargement, worsening ventricular function, or rising venous congestion before the changes become irreversible. Long-term management therefore serves a physiological role: it tracks the balance between compensatory adaptation and decompensation.
Factors That Influence Treatment Choices
Treatment is strongly influenced by severity. Mild tricuspid regurgitation without chamber enlargement or symptoms is often managed by addressing underlying causes and observing for progression. Severe regurgitation, especially when associated with right-sided heart failure, is more likely to require intervention. The degree of annular dilation, leaflet tethering, and right ventricular dysfunction also matters because these features indicate how far the disease has advanced structurally.
The underlying mechanism determines therapy. Functional tricuspid regurgitation caused by ventricular dilation may improve if the driver of dilation is treated. By contrast, primary leaflet disease from endocarditis, rheumatic disease, congenital abnormalities, or trauma is less likely to respond to medical therapy alone because the anatomical defect remains. In such cases, repair or replacement is more often required.
Age and overall health shape the choice between surgery and catheter-based intervention. Frail patients or those with severe lung disease, kidney disease, liver disease, or prior cardiac operations may face a high surgical risk, making transcatheter treatment more attractive. Younger or lower-risk patients may be better candidates for surgery because surgical repair can provide a more durable result.
Associated conditions also influence timing. Tricuspid regurgitation frequently coexists with left-sided valvular disease, pulmonary hypertension, or atrial fibrillation. If another cardiac procedure is already planned, the tricuspid valve may be repaired at the same time to prevent future progression. A prior response to diuretics, rhythm control, or treatment of pulmonary hypertension helps indicate whether the regurgitation is still partly reversible or has become primarily structural.
Potential Risks or Limitations of Treatment
Medical therapy has limits because it does not correct leaflet malcoaptation or annular dilation. Diuretics can reduce congestion but may lead to electrolyte disturbances, kidney dysfunction, or excessive volume depletion if the balance is pushed too far. They relieve the hemodynamic consequences of regurgitation rather than the lesion itself, so symptoms often return if congestion worsens again.
Drugs used to treat associated heart disease may also have indirect limitations. If the right ventricle is already significantly impaired, lowering preload too much can reduce cardiac output. Rhythm control or rhythm restoration in atrial fibrillation may be less effective when atrial and ventricular remodeling is advanced. Similarly, therapies for pulmonary hypertension depend on the specific cause of the elevated pressure and are not universally applicable.
Surgery carries risks related to open-heart procedures, including bleeding, infection, arrhythmias, conduction disturbances, stroke, and prolonged recovery. In tricuspid surgery, the anatomy is often complex because patients frequently have enlarged right-sided chambers, prior cardiac disease, or impaired liver and kidney function from chronic congestion. These comorbidities raise perioperative risk.
Valve replacement has additional limitations. Mechanical prostheses require long-term anticoagulation, which increases bleeding risk. Bioprosthetic valves avoid long-term anticoagulation in many cases but can degenerate over time. Transcatheter therapies have lower procedural invasiveness but may be limited by anatomy, device availability, incomplete reduction of regurgitation, or uncertain long-term durability compared with surgery. In all forms of intervention, late disease with severe right ventricular failure reduces the chance that correcting the valve will fully normalize physiology.
Conclusion
Tricuspid regurgitation is treated with a combination of medical therapy, management of the underlying cause, procedural repair, and in some cases replacement of the valve. The central physiological issue is backward flow from the right ventricle into the right atrium, which produces venous congestion and, over time, chamber enlargement and right ventricular dysfunction. Treatments work by lowering fluid overload, reducing the pressures that distort the valve, correcting arrhythmias or pulmonary hypertension, or directly restoring valve competence through repair or replacement.
The most effective strategy depends on the mechanism of the regurgitation and the stage of right heart involvement. Earlier treatment can interrupt the cycle of annular dilation, leaflet malcoaptation, and progressive right-sided enlargement. In advanced disease, intervention focuses on preventing further decompensation and relieving the hemodynamic burden created by the incompetent valve. Across all treatment types, the underlying aim is the same: to improve one-way flow through the tricuspid valve and reduce the physiological consequences of chronic right-sided volume overload.